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PURPOSE. To determine whether priming of bone marrow mesenchymal stem cells (MSCs)
by signals from injured retina, particularly tumor necrosis factor α (TNFα), increase their
exosomes’ neuroprotective efficacy on retinal ganglion cells (RGCs).
METHODS. MSCs were primed with retinal cell culture conditioned medium, with or with-
out the TNFα blocker etanercept or TNFα prior to isolation of exosomes.MSC conditioned
medium or exosomes were added to rat retinal cultures or human stem cell–derived
retinal ganglion cell (hRGC) cultures, and RGC neuroprotective effects were quantified.
Luminex assays were used to compare primed versus unprimed exosomes.
RESULTS. MSC conditioned medium and exosomes exerted a significant neuroprotective
effect on injured rat and hRGC. This effect was significantly increased after MSCs were
primed with retinal conditioned medium or TNFα. Blocking of TNFα signaling with etan-
ercept prevented priming-induced RGC neuroprotective efficacy. Priming increased PEDF
and VEGF-AA exosomal abundance.
CONCLUSIONS. MSC exosomes promote RGC survival not just in rodent retinal cultures but
also with hRGC. Their efficacy can be further enhanced through TNFα priming with the
mechanism of action potentially mediated, at least in part, through increased levels of
PEDF and VEGF-AA.
Keywords: exosomes, extracellular vesicles, TNFα, mesenchymal stem cells, glaucoma,
priming, retinal ganglion cell
The retina is integral to transforming light information to
Q1
an electrochemical signal and propagating this signal to
the brain. Retinal ganglion cells (RGCs) are the final stage
in the phototransductive pathway of the retina, and their
axons make up the optic nerve. RGCs are acutely suscepti-
ble to optic nerve injury, and their loss, triggered by trauma
or the degenerative neuropathies such as glaucoma, is one
of the leading causes of vision loss worldwide.1 No neuro-
protective treatments are currently available to prevent RGC
degeneration and cell loss.
Bone marrow mesenchymal stem cells (MSCs), a self-
renewing multipotent stem cell population, have demon-
strated significant therapeutic efficacy in models of retinal
trauma and disease.2 Intravitreal injection of MSCs yields
a significant neuroprotective and axogenic effect in animal
models of glaucoma 3,4 and other forms of optic neuropa-
thy.5–7 Evidence strongly suggests that the mechanism of
action is paracrine mediated, dependent on the expansive
secretome of MSCs, which consists of multiple neurotrophic
factors (NTFs) and exosomes.
While there is strong evidence that MSCs exert a signifi-
cant effect on the retina through their signaling cytokines,8,9
signaling in the opposite direction (i.e., signaling from the
injured retina onto MSCs) has not been well studied and
remains poorly understood. It has been suggested that
the expansive secretome of MSCs can be modulated by
signaling molecules from the injured environment, activat-
ing or “priming” the MSCs and further upregulating their
therapeutic potential. In retinal ischemia, where MSC condi-
tioned medium provides a neuroprotective effect and can
partially restore visual function when injected into the vitre-
ous,10 the effect was significantly greater when MSCs had
been subjected to hypoxic conditions prior to condition-
ing of culture,11 suggesting that they can enter a primed
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FIGURE 1. Overview of the Experimental Design.
state in response to injury. Similar observations have been
seen when treating an animal model of stroke with hypoxia-
preconditioned MSCs.12
It is suggested that the inflammatory milieu is responsi-
Q2
ble for priming MSCs, and one candidate is tumor necro-
sis factor α (TNFα), a proinflammatory cytokine that is
expressed by retinal glia and whose receptor, TNFα recep-
tor 1, is expressed by RGCs.13 Retinal glial cells, when
exposed to stressors simulating ischemia or ocular hyper-
tension/glaucoma, upregulated and released TNFα.14–17 This
increased TNFα expression is at least partially responsible
for RGC death, and administration of TNFα neutralizing anti-
bodies reduced RGC apoptosis.18 In rat16,19 and mouse20
models of ocular hypertension, significant elevations in
retinal and optic nerve levels of TNFα were observed. In
human patients with glaucoma, TNFα and TNFα receptor
1 were upregulated compared with age-matched normal
donors.17,21,22 Recently, chronic ocular hypertension was
shown to induce Müller cells to upregulate mRNA and
protein expression of TNFα via ephrinB/EphB and down-
stream PI3K/Akt signaling.14
Our most recent work has demonstrated that MSC-
derived exosomes exert a significant neuroprotective effect
on RGCs.23,24 Exosomes are small extracellular vesicles
that contain microRNA, mRNA, proteins, and lipids. There
is still contention in the field on the appropriate termi-
nology, whether they should be called exosomes or
extracellular vesicles, with exosomes reserved for those
preparations that have used extensive isolation and char-
acterization steps.25 We use the term exosome throughout
this article. Recent studies have shown that their internal
cargo, both mRNA and protein, can be modulated by injury.26
Exposure of endothelial cells to stressors such as hypoxia
and inflammation led to significant changes in protein and
mRNA abundance within subsequently isolated exosomes.
The present study aimed to better understand the changes
that MSC-derived exosomes undergo when exposed to the
injured retinal environment and whether their therapeutic
efficacy can be increased. We primed MSCs by pretreatment
with dissociated retinal cell culture conditioned medium or
TNFα. Primary rat retinal cultures and human stem cell–
derived retinal cultures were then treated with MSC condi-
tioned medium or MSC exosomes. MSC-exosomal proteins
were analyzed, comparing unprimed MSCs to primed
MSCs.
MATERIALS AND METHODS
All reagents were purchased from Sigma (Allentown, PA,
USA) unless otherwise specified. See Figure 1 for an
overview of the experimental design.
MSC Cultures
Human MSCs (bone marrow derived) were purchased
from Lonza (Walkersville, MD, USA) and represented
pooled samples from three donors. CD29+/CD44+/CD73+/
CD90+/CD45− (confirmed by supplier) MSCs were seeded
into T25 or T75 flasks, in a total volume of 5 mL or 15
mL Dulbecco’s modified Eagle’s medium (DMEM), respec-
tively, containing 1% penicillin/streptomycin and 10% fetal
bovine serum (Hyclone Laboratories, Logan, UT, USA) and
at a quantity of 1 × 106 cells and 2 × 106 cells, respec-
tively. Cultures were maintained at 37°C in 5% CO2, the
supplemented medium was changed every three days, and
the cells were passaged when 80% confluent using 0.05%
trypsin/EDTA. For all experiments, MSCs were used at
passages 2 to 5.
Animals
Adult (10 weeks) female Sprague-Dawley rats weighing 170
to 200 g (Charles River, Wilmington, MA, USA) were housed
under accordance with guidelines described in the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research, using protocols approved by the National Eye
Institute Committee on the Use and Care of Animals. These
Primed Exosomes Provide Retinal Neuroprotection IOVS | Month 2020 | Vol. 0 | No. 0 | Article 28266 | 3
guidelines include conditions of 21°C and 55% humidity
under a 12-hout light and dark cycle, food/water given ad
libitum, and being under constant supervision from trained
staff. Animals were killed by rising concentrations of CO2
before extraction of retinae.
Retinal Cell Culture
Eight-well chamber slides (Thermo Fisher Scientific, Cincin-
nati, OH, USA) were precoated with 100 μg/mL poly-D-
lysine for 60 minutes and then with 20 μg/mL laminin for
30 minutes. After culling and ocular dissection, the retinae
of female Sprague-Dawley rats were minced in 1.25 mL
papain (20 U/mL; Worthington Biochem, Lakewood,
NJ, USA; as per manufacturer’s instructions) containing
50 μg/mL DNase I (62.5 μL; Worthington Biochem) and incu-
bated for 90 min at 37°C. The retinal cell suspension was
centrifuged at 300 × g for 5 minutes and the pellet resus-
pended in 1.575 mL Earle’s balanced salt solution (Worthing-
ton Biochem) containing 1.1 mg/mL reconstituted albumin
ovomucoid inhibitor (150 μL; Worthington Biochem) and
56 μg/mL DNase I (75 μL). After adding to the top of
2.5 mL albumin ovomucoid inhibitor (10 mg/mL) to form
a discontinuous density gradient, the retinal cell suspen-
sion was centrifuged at 70 × g for 6 minutes and the cell
pellet resuspended in 1 mL of supplemented Neurobasal-A
(25 mL Neurobasal-A; Life Technologies, Carlsbad, CA, USA),
1× concentration of B27 supplement (Life Technologies),
0.5 mM L-glutamine (62.5 μL; Thermo Fisher Scientific), and
50 μg/mL gentamycin (125 μL; Thermo Fisher Scientific).
Retinal cells were then seeded into eight-well chamber slides
at a concentration of 125,000 cells/well. After 72 hours in
culture, retinal cell culture conditioned medium (from reti-
nae collected from three animals) was collected to be used
in MSC priming as below.
MSC Priming
MSC cultures were primed by treating with retinal cell
culture conditioned medium, prepared as above. Our previ-
ous studies have demonstrated that coculture of 50,000 MSCs
with 125,000 dissociated retinal cells in 500 μL leads to
significant neuroprotection and neuritogenesis.7,8 Therefore,
500,000 MSCs in a T75 flask were primed by treatment with
conditioned medium from 1,250,000 dissociated retinal cells.
The retinal cell culture conditioned medium was concen-
trated using Amicon 10,000 mw filters (Millipore, Burling-Q3
ton, MA, USA) prior to treatment of MSCs. This approach
concentrated the medium by approximately 10-fold, mean-
ing instead of adding 4 mL of retinal conditioned medium
(from 1,250,000 dissociated retinal cells) to a single T75 flask
containing MSCs, we only needed to add 400 μL.
In place of retinal cell culture conditioned medium, MSCs
were also primed with recombinant human TNFα (Gibco;Q4
10ng/mL) for 48 hours.27 Retinal cell culture conditioned
medium was also combined with the TNFα blocker, etaner-
cept, at a concentration of 0.5 μg/mL according to previous
dose-response studies in vitro.28
After culture in the priming medium (retinal conditioned
medium or TNFα) for 48 hours, MSCs were washed in PBS
three times, passaged, and grown in fresh DMEM contain-
ing 10% exosome depleted serum. After a further 48 hours
in culture, MSC division rate was calculated and conditioned
medium was collected (from three separate cultures) for the
TABLE. Antibodies Used in Immunocytochemistry (ICC) and West-
ern Blot (WB)
Antigen Dilution Supplier Catalogue No.
βIII-Tubulin 1:500 (ICC) Sigma #T-8660
Syntentin 1 1:1000 (WB) Abcam #Ab133267
CD63 1:1000 (WB) System Bio #Exoab-CD63-A1
ApoA1 1:1000 (WB) Abcam #ab7613
ApoB 1:1000 (WB) Abcam #ab20737
HSC70 1:5000 (WB) Santa Cruz #sc-7298
Mouse IgG HRP 1:2000 (WB) GE Healthcare #NA-931
Mouse IgG 488 1:400 (ICC) Thermo Fisher #A-11001
Mouse IgG HRP 1:2000 (WB) GE Healthcare #NA-931
Rabbit IgG HRP 1:10,000 (WB) Cell Signalling #7074
HRP, XXX.
Luminex assay, exosome isolation, and assessment of neuro-
protective/neuritogenic efficacy in retinal cultures.
Exosome Isolation
Exosomes were isolated from MSCs using ExoQuick-TC
Q5
(System Biosciences, Mountain View, CA, USA) per the
manufacturer’s instructions. Briefly, conditioned medium
was centrifuged at 3000 × g for 15 minutes before incu-
bation with ExoQuick reagent overnight at 4°C (1:10 ratio
with medium). The solution was centrifuged at 1500 × g for
15 minutes a final time before resuspension of exosome
pellet in sterile PBS. The exosome preparation was then
passed through a 0.22-μm filter to remove large microvesi-
cles and apoptotic bodies. Exosomes were characterized via
Western blot by their positive staining for the exosome mark-
ers Syntenin 1 and CD63 and negative staining for high/low-
density lipoprotein markers ApoA1 and ApoB.24 Briefly,
exosomes were lysed in passive lysis buffer (Promega,
Madison, WI, USA; #E1531) and protein samples (20 μg)
were separated on 4% to 12% Bis-Tris protein gels at
150 V for 40 minutes. After transference to polyvinyli-
dene fluoride membranes and blocking in 10% Western blot
blocking buffer (Roche, Basel, Switzerland) in Tris-buffered
saline (TBS), proteins were stained overnight in primary
antibody (Table) diluted in TBS. Samples were washed
3 × 5 minutes in TBST, stained for 1 hour with secondary Q6
antibody (Table) in TBS, and washed 3 × 5 minutes in TBST
before detection with Immobilon ECL reagents (Millipore,
Burlington, MA, USA). Densitometry of Western blot bands
was analyzed using ImageJ software (National Institutes of
Health, Bethesda, MD, USA) as previously reported.24 All
exosomes samples used in the study comprised exosomes
pooled from three MSC donors.
The concentration and size distribution of exosomes were
characterized using a NanoSight LM10 instrument (Malvern,
Worcester, MA, USA), equipped with a 405-nm LM12 module
and EM-CCD camera (DL-658-OEM-630; Andor, Concord,
MA, USA). Three videos were captured per sample with a
camera level of 10. Videos were analyzed with a detection
threshold of 2, automatic blur size, and 12.9–13.1 pix maxi-
mum jump size. Slider gain was set to 80 and a total of 567
frames were taken.
Retinal Culture Treatment
To assess neuroprotective and neuritogenic effects of MSCs
on RGCs, retinal cells were isolated as above and cultured at
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a density of 125,000 cells/300 μL/well in eight-well cham-
ber slides. Retinal cultures were treated with MSC condi-
tioned medium (primed or unprimed) and incubated for
72 hours at 37°C before fixation and immunocytochemical
staining of RGCs with βIII-tubulin as detailed below. MSC
conditioned medium treatments were 50 μL (concentrated
using Amicon 10,000 mw filters) per well and derived from
50,000 MSCs over 48 hours. Selected cultures were treated
human recombinant CNTF as a positive control (50 ng/mL).Q7
For this study, large spherical βIII-tubulin+ rat retinal cells,29
which can be identified by preferential βIII-tubulin inten-
sity around the axonal base, are referred to as RGCs. Previ-
ous immunocytochemical analysis of these cultures in our
laboratory demonstrates that 60% of these retinal cells are
neurons (neurofilament+/βIII-tubulin+), of which 10% are
Thy1+ RGCs and possess the unique βIII-tubulin stain-
ing pattern described above.30 Retinal cultures consisted of
cultures from three different animals, three wells per animal.
Human Stem Cell–Derived RGCs (hRGCs)
An H9-derived human embryonic stem cell line engineered
such that tdTomato and mouse THY1.2 were knocked into
the POU4F2 (BRN3B) locus was differentiated into humanQ8
RGCs (hRGCs) according to the published protocol.31,32
Briefly, cells are plated and grown on Matrigel (Corning, NY,
USA) coated plates in mTeSR medium (Stem Cell Technolo-
gies, Vancouver, Canada) supplemented with blebbistatin
(5 μM).Medium is switched on day 1 to retinal differentiation
medium (RDM; DMEM/F12 + Neurobasal A medium [mixed
50:50], 1× Glutamax, 1× anti-anti, 1× N2 supplement, and
1× B27 supplement; Thermo Fisher Scientific) and cultured
in this medium up until day 40. Small molecules are added as
follows: days 1 to 6, dorsomorphin (1 μM), inducer of defini-
tive endoderm 2 (2.5 μM; Stem Cell Technologies), forskolin
(25 μM), and nicotinamide (10 μM); days 6 to 10, forskolin
and nicotinamide; days 10 to 18, forskolin; days 18 to 30,
forskolin and DAPT (10 μM); and days 30 to 40, RDM alone.Q9
Note that the cultures contain hRGCs as well as other retinal
cells but are called hRGCs for the sake of brevity.
Unlike adult rodent-derived RGC cultures that degener-
ate in culture without intervention, hRGCs do not degener-
ate unless triggered to do so. To induce stress, damage, and
subsequent death, hRGCs were treated with 1 μM colchicine
as previously described.32 Exosome treatment was given
at the same time, and after 48 hours, cells were fixed as
detailed below without the need for immunocytochemical
staining. Three wells were used per treatment group and
were repeated three times on separate days and with sepa-
rate cultures.
Immunocytochemistry
Retinal cells were fixed in 4% paraformaldehyde in PBS for
10 minutes, washed for 3 × 10 minutes in PBS, blocked in
blocking solution (3% bovine serum albumin [g/mL], 0.1%
Triton X-100 in PBS) for 20 minutes, and incubated with
primary antibody (Table) diluted at 1:500 in antibody dilut-
ing buffer (ADB; 0.5% bovine serum albumin, 0.3% Tween-
20 in PBS) for 1 hour at room temperature. Cells were
then washed for 3 × 10 minutes in PBS, incubated with
the secondary antibody (Table) diluted in ADB for 1 hour
at room temperature, washed for 3 × 10 minutes in PBS,
mounted in Vectorshield mounting medium containing DAPI
(Vector Laboratories, Peterborough, UK), and stored at 4°C.
Enzyme-Linked Immunosorbent Assay (ELISA)
To quantify the amount of TNFα released by cultured retina,
conditioned medium from three separate cultures/animals
was collected and assayed using a duoset ELISA kit
according to the manufacturer’s instructions (R&D Systems,
Minneapolis, MN, USA). Briefly, a standard curve was
constructed using TNFα standards and test samples of condi-
tioned medium at increasing dilutions, run in duplicate with
TNFα concentrations extrapolated from the standard curve.
Multiplex Bead Immunoassay (Luminex)
Conditioned media from three separate cultures of MSCs
and retina were analyzed using a neurotrophic multiplex
Luminex kit (Thermo Fisher Scientific) according to the
manufacturer’s instructions and using the same principles
described in the ELISA section. Assays were run using a
Luminex-100 system (Luminex, Austin, TX, USA).
Microscopy and Analysis
Retinal cultures were imaged using an LSM700 laser scan-
ning confocal microscope (Carl Zeiss, Inc., Thornwood, NY,
USA). For rat retinal cultures, the entire eight-well chamber
was images and the number of βIII-tubulin+ RGC/RGC with
neurites was quantified. For hRGC cultures, 1-mm2 scans
were collected and the number of BRN3B+ RGCs was quan-
tified. Counts were conducted manually by an individual
masked to the treatment groups. All cell cultures (rat and
human) were performed both in triplicate and three sepa-
rate times (n = 3).
Statistics
Animal numbers were determined beforehand using a power
calculation (Gpower). All statistical tests were performed
using SPSS 17.0 (IBM SPSS, Inc., Chicago, IL, USA) and data
presented as mean ± standard error of the mean (SEM) with
graphs constructed using SigmaPlot (San Jose, CA, USA).
The Shapiro-Wilkes test was used to ensure all data were
normally distributed before parametric testing using a one-
way analysis of variance (ANOVA) with a Tukey post hoc
test. Statistical differences were considered significant at P
values <0.05. For the qRT-PCR, data were compared by a Q10
Student’s t-test and statistical significance set at P < 0.001.
RESULTS
MSC Conditioned Medium Is Neuroprotective in
Adult Rat Retinal Cultures, but Only When Primed
We first determined the neuroprotective and neuritogenic
properties of retinal cell culture and TNFα-primed MSC
conditioned medium in freshly isolated rat retinal cells. In
untreated controls, 92 ± 12 (mean ± SEM) RGCs survived
with 36.7 ± 1.5 RGCs containing neurites (Figs. 2A, 2E,
2F). Retinal cells cultured with the positive control CNTF
showed 276.3 ± 12.7 surviving RGCs and 113.7 ± 5.7 RGCs
with neurites (Figs. 2B, 2E, 2F) while treatment of retinal
cells with unprimed MSC conditioned medium promoted
the survival of 110.7 ± 10.7 RGCs and 58.3 ± 16.6 RGCs
with neurites (Figs. 2C, 2E, 2F). However, treatment of reti-
nal cells with retinal cell culture–primed MSC conditioned
medium (referred to simply as “primed MSC conditioned
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FIGURE 2. MSC conditioned medium treatment of heterogenous retinal cultures. Heterogenous adult rat retinal cultures were left for three
days either untreated (negative control; A), treated with CNTF (positive control; B), treated with MSC conditioned medium (C), treated
with primed MSC conditioned medium without (D) or with etanercept (TNFα blocker) added during priming, or treated with TNFα primed
MSC conditioned medium without or with etanercept added during priming (scale bar: 50 μm). The number of RGCs (E), denoted by their
asymmetrical βIII-tubulin staining, and the number of RGCs with neurites (F) were quantified (n = 3). Asterisks indicate a significant increase
in RGC neuroprotection/neuritogenesis in comparison to untreated control/unprimed MSC conditioned medium (P < 0.05) and includes
CNTF treatment and primed MSC (via retinal medium or TNFα) conditioned medium treatment.
medium”) elicited significant neuroprotection (255 ± 20.5
RGCs) and neuritogenesis (115 ± 25.9 RGCs with neurites)
(Figs. 2D, 2E, 2F) compared with unprimed MSC condi-
tioned medium and untreated controls (Fig. 2). Significant
neuroprotection and neuritogenesis, similar to primed MSC
conditioned medium, was also achieved after treatment with
conditioned medium from MSCs primed with TNFα (285.3 ±
8.5 RGCs and 113.7 ± 5.7 RGCs with neurites, respectively)
(Figs. 2E, 2F), and both priming methods were equivalently
neuroprotective and neuritogenic as CNTF-treated positive
control cultures. If etanercept, a potent blocker of TNFα,
was included in the MSC culture during priming, the primed
MSC conditioned medium (primed via treatment with rat
retinal cultures or TNFα) no longer elicited neuroprotec-
tion (90.7 ± 3.8 and 100.7 ± 10.8 RGCs, respectively) or
neuritogenesis (42 ± 5.6 and 43.7 ± 9.5 RGCs with neurites,
respectively) (Figs. 2E, 2F). These results demonstrate that
both primed MSC conditioned medium and MSC conditioned
medium primed with TNFα cause significant RGC protection
and neurite outgrowth. In addition, the ablation of priming
by etanercept demonstrates that retinal conditioned medium
primed MSCs primarily through TNFα.
MSC Exosomes Are Neuroprotective in hRGC
Cultures and More Effective After Priming
We next determined if MSC exosomes were neuroprotec-
tive to hRGCs and whether priming with TNFα potenti-
ated the neuroprotective effects. Whereas rodent retinal
cultures degenerate spontaneously in culture, hRGCs require
colchicine to trigger their degeneration.31,32 In untreated
cells + vehicle (PBS), abundant BRN3B+ hRGCs were
detected in culture (Figs. 3A, 3F) while the addition of
colchicine to hRGC cultures caused an approximate 80% loss
of hRGCs (107.5 ± 9.3 hRGCs; Figs. 3B, 3F) compared with
uninjured cultures (539 ± 39 hRGCs; Figs. 3A, 3F). Treat-
ment with MSC exosomes led to significant hRGC neuro-
protection (208.1 ± 14.2 hRGCs; Figs. 3D, 3F) compared
with untreated, colchicine-injured cultures and was equiv-
alent to CNTF-treated positive control cultures (224.8 ± 60.7
hRGCs; Figs. 3C, 3F). Moreover, treatment with TNFα-primed
MSC exosomes led to a significantly enhanced neuroprotec-
tive effect (355.7 ± 7.3 hRGCs) compared with MSC exosome
treatment (Figs. 3E, 3F). These results demonstrate that MSC
exosomes and TNFα-primed MSC exosomes provide signif-
icant neuroprotection to hRGCs cultured in the presence of
“injury-inducing” colchicine.
Retinal Conditioned Medium, Used to Prime
MSCs, Contains TNFα
With retinal conditioned medium reliably priming MSC
and etanercept, a TNFα blocker, inhibiting priming, we
next sought to confirm that conditioned medium from reti-
nal cell cultures contained TNFα. TNFα was absent from
supplemented Neurobasal-A, but significant concentrations
Primed Exosomes Provide Retinal Neuroprotection IOVS | Month 2020 | Vol. 0 | No. 0 | Article 28266 | 6
FIGURE 3. Exosome treatment of heterogeneous human stem cell–derived retinal cultures. Heterogeneous retinal cultures derived
from human stem cells were left uninjured/untreated (A), injured with colchicine but untreated (negative control; B), injured with
colchicine/treated with CNTF (positive control; C), injured with colchicine/treated with MSC exosomes (D), or injured with colchicine/treated
with TNFα primed MSC exosomes (E; scale bar: 250 μm). The number of RGCs (F), identified by the Brn3b expression, were quantified
(n = 3). Asterisks indicate significant difference from untreated/colchicine-injured control at P < 0.05). Asterisks also indicate a significant
increase in RGC neuroprotection in comparison to untreated/colchicine-injured control (P < 0.05) and include CNTF treatment, exosome
treatment, and TNFα primed exosome treatment. Furthermore, significant difference was also observed between exosome treatment and
TNFα primed exosome treatment (double asterisks).
were observed after retinal cell culture conditioning for
24 hours (518 ± 109.9 pg/mL) and 48 hours (1175.4 ±
154.9 pg/mL; Fig. 4). These results demonstrate that signif-
icant titers of TNFα were present in conditioned medium
from retinal cell cultures.
Priming Had No Effect on Division/Exosome
Secretion Rate
We then investigated if priming MSCs with TNFα altered
their division rate or secretion of exosomes. MSC divi-
sion rate following TNFα priming (0.76 ± 0.23 divisions/24
hours) was not significantly different from the division rate
of unprimed MSCs (0.79 ± 0.21 divisions/24 hours; Fig. 5A).
MSC exosome secretion rate following TNFα priming (1.88 *
106 ± 5.34 * 105 exosomes/100,000 cells/24 hours) trended
toward but was not significantly higher than the exosome
secretion rate of unprimed MSCs (1.25 * 106 ± 2.75 * 105
exosomes/100,000 cells/24 hours; Fig. 5B). These results
showed that MSC division rate and secretion of exosomes
were unaffected by priming.
Priming MSCs Significantly Increases Exosomal
PEDF, VEGF-A, and PDGF-AA Q11
Q12We next determined the abundance of a number of NTFs
in exosome preparations from MSC conditioned medium,
retinal cell culture conditioned medium, and primed MSC
conditioned medium. We observed that PEDF abundance
was significantly enhanced in primed MSC conditioned
medium and TNFα primed conditioned medium (3693 ± 232
pg/mL and 4469 ± 261 pg/mL, respectively) compared with
unprimed MSCs (1408 ± 93 pg/mL; Fig. 6). VEGF-A abun-
dance was also significantly enhanced in MSC conditioned
medium and TNFα primed conditioned medium (1263 ±
38 pg/mL and 1063 ± 40 pg/mL, respectively) compared
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FIGURE 4. TNFα secretion by heterogeneous retinal culture. Reti-
nal culture conditioned medium, collected after 24 or 48 hours
in culture (or unconditioned controls), was assayed using a TNFα
ELISA (n = 3; black lines indicate significant difference at P < 0.05).
with unprimed MSCs (514 ± 37 pg/mL). PDGF-AA abun-
dance was significantly enhanced after priming (5.74 ± 0.65
pg/mL) but not after TNFα priming (3.15 ± 0.49 pg/mL)
compared with unprimed MSCs (2.86 ± 0.69 pg/mL). BDNF,Q13
VEGF-C, NT-4, FGF, and PDGF-CC were detectable but not
significantly increased after priming/TNFα priming. Beta-
NGF, PDGF-DD, PDGF-BB, EGF, VEGF-D, and PDGF-ABQ14
were possible analytes in the present assay but were not
detected.
DISCUSSION
The present study demonstrates that MSCs are receptive to
priming following their introduction to an injured environ-
ment. In the case of the injured retina, MSCs are primed
due to the release of TNFα. After priming, MSCs exert a
significantly greater neuroprotective effect on injured RGCs,
both rat and human derived. Congruent with our previous
work, this effect is paracrine mediated,8 likely through their
released exosomes.33 The augmented effect TNFα priming
afforded MSC exosomes possibly involves an increase in
exosomal NTFs.
TNFα acts through two receptors, TNF receptors 1 and 2,
with receptor 2 being the likely candidate for its actions on
neural cells.34 Previous work has demonstrated that stimula-
tion of MSCs by TNFα significantly upregulated production
of NTFs, including VEGF, HGF, and IGF.35 MAPK inhibitors Q15
decreased the production of these NTFs while they had Q16
no effect on baseline secretion, suggesting the upregulated
secretion is a distinct mechanism. In a separate study, MSCs
exposed to either hypoxic conditions or TNFα are activated
through the NF-κB pathway and upregulate their secretion
of several NTFs, including VEGF, FGF2, IGF-1, and HGF.36
As well as secretion of NTFs, migration into injured tissue
is an important property integral to the regenerative poten-
tial of MSCs. Treatment of MSCs with TNFα increased their
invasion and migration through the extracellular matrix,
attributed partially to the upregulation of intracellular adhe-
sion molecule 137 and vascular cell adhesion protein 1.38
In the present study, we demonstrated that retinal condi-
tioned medium was ineffective at priming MSCs if etaner-
cept, a TNFα inhibitor, was included, suggesting TNFα is a
critical mediator in priming MSCs in this model.
Both PEDF and VEGF-AA, which were found to be signif-
icantly upregulated after TNFα priming of MSCs, are known
neuroprotective agents for injured RGCs. Müller cells exert
a neuroprotective effect on RGCs through the secretion
of PEDF,39 while delivery of PEDF into retinal cultures or
rat eyes after optic nerve crush leads to significant RGC
neuroprotection.40 Delivery of VEGF into ocular hyperten-
sive eyes leads to significant RGC neuroprotection while
also upregulating PEDF.41 A separate study in an ocular
hypertensive model demonstrated that VEGF-A promoted
RGC neuroprotection via direct activation of the VEGF
receptor 2 and signaling through the phosphoinositide-3-
kinase/Akt pathway.42 The same group showed that treat-
ing the same primary retinal cultures used in this study
with VEGF-A elicited 50% more RGC neuroprotection than
untreated controls. While comparative analysis is difficult
as the referenced study used hypoxia to injure the cultured
RGCs, exosomes appear to be more efficacious, likely due
FIGURE 5. Division and exosome secretion rate of primed MSCs. (A) The mean number of divisions of unprimed MSCs and those primed
by TNFα. (B) The mean number of exosomes secreted by unprimed MSCs and those primed by TNFα (n = 3, no significant differences
observed at P > 0.05).
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FIGURE 6. Luminex analysis of primed MSC protein secretome. Luminex analysis was performed on control MSC growth media, control
retinal conditioned medium, unprimed MSC conditioned medium, primed MSC conditioned medium, and TNFα primed conditioned medium
(n = 3; black lines indicate significant differences between primed and unprimed at P < 0.05). Beta-NGF, PDGF-DD, PDGF-BB, EGF, VEGF-D,
and PDGF-AB were not detected.
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to their cargo containing multiple NTFs. In comparison to
VEGF, PEDF appears to act, at least partially, through reti-
nal glia, leading to suppression of RGC caspase 2.43 Treat-
ment of RGC cultures with PEDF leads to a 63% increase
in RGC survival in comparison to untreated cultures, which,
similar to VEGF-A, cannot account for the full neuroprotec-
tive effect elicited by exosomes. PDGF-AA is also a potent
neuroprotective for RGCs and an integral component of
the neuroprotective secretome of MSCs.9 Interestingly, while
PDGF-AA abundance in or associated with exosomes was
upregulated following MSC priming with retinal conditioned
medium, this was not seen when MSCs were primed with
TNFα. While the present study focused on TNFα, it is appar-
ent that other injury-associated cytokines are involved in
the priming of MSCs. While these NTFs were identified in
our exosome samples, it is possible they were not in the
cargo but rather externally associated with the exosomes.
A previous study performing proteomic analysis of extra-
cellular vesicles demonstrated the presence of PEDF, with
the authors suggesting that the protein is extracellular and
associated with the exosome.44 Further study is required to
confirm the importance of these cytokines in the improved
neuroprotective efficacy of primed MSCs.
We tested our samples in two in vitro models of RGC
death. The first was a primary culture of adult rat RGCs.
We have already demonstrated the neuroprotective efficacy
of MSC exosomes in this model,33 and thus, it served as a
reliable system with which to compare the improved effi-
cacy of primed MSC exosomes/conditioned medium. The
second in vitro model was hRGCs derived from human stem
cell cultures.31,32 To our knowledge, this is the first time
exosomes have been used as a therapeutic on hRGCs, and
our results not only reinforce our previous findings in rodent
models but also add credibility to the improved therapeutic
efficacy after priming.
In conclusion, the present study demonstrated the feasi-
bility and ease by which the efficacy of MSCs and their
exosomes can be improved. TNFα is one such priming candi-
date, and the effects appear to involve the upregulation
of neurotrophic proteins that are released in, or associ-
ated with, exosomes. Finally, we build upon the established
literature demonstrating a neuroprotective efficacy of MSC
exosomes by showing that their potential also extends
to human retina. Future studies will be directed toward
improving exosomes’ efficacy while ensuring their safety
and tolerance, having translation into patients as the rapidly
approaching goal.
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